Emerging nanotechnology backed formulations for the management of atopic dermatitis

Atopic dermatitis is a prevalent chronic skin inflammation affecting 2.1 to 4.1% of adults globally. The complexity of its pathogenesis and the relapsing nature make it challenging to treat. Current treatments follow European Academy of Dermatology and Venerology guidelines, but advanced cases with recurring lesions lack effective therapies. To address this gap, researchers are exploring nanotechnology for targeted drug delivery. Nanoparticles offer benefits such as improved drug retention, stability, controlled release and targeted delivery through the disrupted epidermal barrier. This integrated review evaluates the current state of AD treatment and highlights the potential of novel nano-formulations as a promising approach to address the disease. Atopic dermatitis is a skin disease and difficult to treat. It happens because of various reasons like skin barrier problems, weather conditions, irritants and allergens from microorganisms. The current treatments do not fully cure the disease, and there's no established treatment for it but there is hope in nanotechnology and nanoformulations. Nano formulations are preparations with particles between 8 and 250 nm. Moreover, studies with animals and humans show promising results with nanoformulations. This review paper explores different ways to use nanotechnology to treat atopic dermatitis. It might lead to exciting new treatments in the future. Atopic dermatitis affects 2.1–4.1% of adults globally, posing challenges due to its relapsing nature. Nanotechnology explores targeted drug delivery with improved retention and precise release. Figure showing all the nanocarriers targeted for atopic dermatitis and their site of action on the skin.